This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Surrozen, Inc. (SRZN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
by Zacks Equity Research
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
Zacks.com featured highlights include Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity
by Zacks Equity Research
Lamb Weston, NeoGenomics, Surrozen, KE Holdings and Insperity are part of the Zacks Screen of the Week article.
Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in Nektar Therapeutics (NKTR) stock now is a good idea despite its several pipeline setbacks.
5 Top Stocks Likely to Come Up With Earnings Beat
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. Tap Lamb Weston (LW), NeoGenomics (NEO), Surrozen (SRZN), KE Hodlings (BEKE) and Insperity (NSP).
Here's Why You Should Invest in Larimar (LRMR) Stock Now
by Zacks Equity Research
Here we discuss some reasons why investing in Larimar Therapeutics (LRMR) stock now is a good idea.
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
by Zacks Equity Research
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
New Strong Buy Stocks for April 12th
by Zacks Equity Research
CELU, MGI, LRMR, EQRX and SRZN have been added to the Zacks Rank #1 (Strong Buy) List on April 12, 2023.
Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Surrozen, Inc. (SRZN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.